Drugs / Probio-Tec BG-VCap-6.5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03383874 | Sep 2018 → Sep 2024 | mood disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02819960 Comparator | Mar 2016 → Aug 2022 | cancer, diarrheal disease | S&D Pharma SK s.r.o. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probio-Tec BG-VCap-6.5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383874 ↗ |
| Action | Inhibit | “some probiotic bacteria, reduce activity of intestinal beta-D-glucuronidase and therefore these bacteria could be applied in the prevention of diarrhea” NCT02819960 ↗ |
| Modality | Other / unclassified | “The objective of this phase III. trial is to determine effectiveness of the probiotic formula Probio-Tec® BG-VCap-6.5” NCT02819960 ↗ |
| Route | Oral | “Intervention: Probiotic formula Probio-Tec® BG-VCap-6.5 will be administered at a dose of 3x1 cps per day orally for 6 weeks.” NCT02819960 ↗ |